List of life sciences

New Data Demonstrate that the Utilization of TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus over the Standard of Care Alone

Retrieved on: 
Tuesday, October 25, 2022

A diagnosis of low-grade dysplasia in Barretts esophagus warrants expert pathology review, as these patients may have a significant risk of developing esophageal cancer.

Key Points: 
  • A diagnosis of low-grade dysplasia in Barretts esophagus warrants expert pathology review, as these patients may have a significant risk of developing esophageal cancer.
  • The use of TissueCypher test results can reduce inconsistencies in management decisions for Barretts esophagus patients with low-grade dysplasia.
  • In the other arm, patients were managed by the current standard of care with additional guidance from TissueCypher test results.
  • The TissueCypher Barretts Esophagus test is Castles precision medicine test designed to predict future development of high-grade dysplasia (HGD) and/or esophageal cancer in patients with Barretts esophagus (BE).

Orionis Biosciences Demonstrates Platform Capabilities of Genome-scale Molecular Glue Discovery and Rational Design at Targeted Protein Degradation Summit

Retrieved on: 
Wednesday, October 26, 2022

The data include platform achievements for ligase-centric and target-centric discovery of molecular glue compounds with potential to modulate previously intractable disease targets.

Key Points: 
  • The data include platform achievements for ligase-centric and target-centric discovery of molecular glue compounds with potential to modulate previously intractable disease targets.
  • A lack of systematic, scalable discovery and design approaches to molecular glues has, however, limited the field, said Riccardo Sabatini, Ph.D., Chief Data Scientist at Orionis.
  • Today we are presenting new data that demonstrate the ability of Orionis proprietary Allo-GlueTM platform to transform glue discovery into a genome-scale, high throughput and rational discovery paradigm.
  • Our large-scale interrogation of small molecule-triggered protein-protein interactions makes it abundantly clear that molecular glue mechanisms are more common than previously appreciated.

Resolve Biosciences Appoints Chief Commercial Officer to Drive Worldwide Adoption of Molecular Cartography™ Workflow

Retrieved on: 
Tuesday, October 25, 2022

Resolve Biosciences , the pioneer in Molecular Cartography technology, today announced the appointment of Paul Steinberg as Chief Commercial Officer.

Key Points: 
  • Resolve Biosciences , the pioneer in Molecular Cartography technology, today announced the appointment of Paul Steinberg as Chief Commercial Officer.
  • Most recently, he served as the Chief Commercial Officer at LevitasBio, a provider of innovative cellular processing and characterization technologies.
  • I am eager to join this talented team and to accelerate the process of delivering powerful Molecular Cartography results to labs around the world.
  • Resolve Biosciences, the Resolve Biosciences logo, and Molecular Cartography are trademarks of Resolve Biosciences.

Clarify Health Recognized by Frost & Sullivan as a Healthcare Data Analytics Market Leader in 2022

Retrieved on: 
Tuesday, October 25, 2022

Clarify Health , a leading cloud analytics and value-based payments platform company, today announced it has been recognized by Frost & Sullivan as an industry leader in the Frost Radar: Healthcare Data Analytics 2022 Report .

Key Points: 
  • Clarify Health , a leading cloud analytics and value-based payments platform company, today announced it has been recognized by Frost & Sullivan as an industry leader in the Frost Radar: Healthcare Data Analytics 2022 Report .
  • Clarify Health was ranked as a leader on its Innovation Index based on the companys scalability, R&D efficiency, and product innovation.
  • (Graphic: Business Wire)
    Clarify Health stands out in its understanding of the market, clear strategy roadmap, and forward-thinking vision, said Delfina Huergo, Research Analyst, Health & Life Sciences, Frost & Sullivan.
  • The Clarify Atlas Platform offers healthcare data analytics solutions to health plans, providers and life sciences companies.

Be The Match BioTherapies® Expands Presence In the San Francisco Bay Area For Allogeneic Therapy Development and Commercialization

Retrieved on: 
Tuesday, October 25, 2022

Chris McClain, Senior Vice President, will work from the San Francisco area to support an expanding client base seeking high-quality cellular source material for allogeneic therapy development and commercialization to deliver time-critical cell therapies to patients.

Key Points: 
  • Chris McClain, Senior Vice President, will work from the San Francisco area to support an expanding client base seeking high-quality cellular source material for allogeneic therapy development and commercialization to deliver time-critical cell therapies to patients.
  • Since 2016 Be The Match BioTherapies has provided cell sourcing and supply chain management services for the development of allogeneic cell therapies.
  • Chris McClain leads the sales and business development team for Be The Match BioTherapies.
  • Be The Match BioTherapies is the only cell and gene therapy solutions provider with customizable services to support the end-to-end cell therapy supply chain.

ZIVO Bioscience Announces Plans for a New Streamlined, Focused Corporate Structure and Establishes the ZIVOLife Agtech Business

Retrieved on: 
Monday, October 24, 2022

The new structure allows ZIVOLife to raise capital from third parties to advance and expand its business.

Key Points: 
  • The new structure allows ZIVOLife to raise capital from third parties to advance and expand its business.
  • To the extent ZIVOLife attracts additional third-party investment in the future, ZIVO Biosciences interest in the operations of ZIVOLife may be diluted.
  • ZIVO Bioscience has made important progress to date, yet there is much more to do that is best accomplished under this new structure.
  • ZIVO Bioscience management will host a conference call in early November to discuss this new corporate structure and answer questions.

Resolve Biosciences Secures $71 Million Series B Financing to Accelerate Commercial Expansion to Meet Global Demand for Molecular Cartography™ Workflow

Retrieved on: 
Monday, October 24, 2022

Resolve Biosciences , the pioneer in Molecular Cartography technology, today announced it has secured a $71 million Series B financing.

Key Points: 
  • Resolve Biosciences , the pioneer in Molecular Cartography technology, today announced it has secured a $71 million Series B financing.
  • Resolve intends to build on its successful commercial launch and use the proceeds from the financing to rapidly scale operations and accelerate product development to meet growing demand worldwide.
  • Resolve Biosciences is applying the power of Molecular Cartography to enable scientists to gain new insights based on the highest-resolution view of spatial biology.
  • Resolve Biosciences, the Resolve Biosciences logo, and Molecular Cartography are trademarks of Resolve Biosciences.

Sagimet Biosciences Announces Appointment of David Happel to Chief Executive Officer; Dr. George Kemble to Transition to Executive Chairman Role

Retrieved on: 
Monday, October 24, 2022

Sagimet Biosciences, a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, announced today that it has appointed David Happel as chief executive officer, replacing George Kemble, PhD, who will transition to become executive chairman of the board.

Key Points: 
  • Sagimet Biosciences, a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, announced today that it has appointed David Happel as chief executive officer, replacing George Kemble, PhD, who will transition to become executive chairman of the board.
  • View the full release here: https://www.businesswire.com/news/home/20221024005305/en/
    David Happel, chief executive officer of Sagimet Biosciences (Photo: Business Wire)
    We are pleased to welcome Dave as our new chief executive officer.
  • As Sagimet anticipates moving forward to late-stage clinical trials with our lead program, denifanstat, Daves experience will be instrumental to the companys growth.
  • We are fortunate to benefit from Georges continued contributions and expertise in his new role as executive chairman of the board.

MedTechVets Appoints Patrice Sutherland, Enterprise Executive Director at Integra LifeScience, as New Board Chairperson

Retrieved on: 
Monday, October 24, 2022

Patrice Sutherland, enterprise executive director at Integra Life Sciences, has been appointed Chairperson of the Board of Directors for MedTechVets, a nonprofit organization that helps military Veterans transition and gain employment at Medical Technology and Life Science companies.

Key Points: 
  • Patrice Sutherland, enterprise executive director at Integra Life Sciences, has been appointed Chairperson of the Board of Directors for MedTechVets, a nonprofit organization that helps military Veterans transition and gain employment at Medical Technology and Life Science companies.
  • View the full release here: https://www.businesswire.com/news/home/20221024005178/en/
    "I am humbled and honored to have been asked to take on this very special role, said Sutherland.
  • It has been a joy to serve the community as the chair of MedTechVets and I am so excited to congratulate Patrice as the new Chair.
  • Since joining the MedTechVets board in 2021, Sutherland has personally helped many Veterans transition to careers in the Medical Technology and Life Sciences industries.

Scenic Biotech Appoints Jens Würthner as Chief Medical Officer

Retrieved on: 
Monday, October 24, 2022

Scenic Biotech , a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, announced today the appointment of Jens Wrthner, MD, PhD, as Chief Medical Officer.

Key Points: 
  • Scenic Biotech , a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, announced today the appointment of Jens Wrthner, MD, PhD, as Chief Medical Officer.
  • Dr. Wrthner brings Scenic Biotech 20 years of clinical development expertise.
  • I am excited to work alongside Oscar and everyone at Scenic Biotech as we advance a broad portfolio of disease-modifying therapeutics for the benefit of patients, added Dr. Jens Wrthner, Chief Medical Officer of Scenic Biotech.
  • By understanding the genomes power to correct toward health, Scenic Biotech will bring novel therapeutics to patients in need.